Browsing Tag
vutrisiran
5 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Can Alnylam Pharmaceuticals’ vutrisiran reverse cardiac damage? HELIOS-B Phase 3 ATTR-CM trial says yes
New HELIOS-B data shows vutrisiran improves cardiac structure and kidney outcomes in ATTR-CM. Find out how Alnylam’s RNAi drug is reshaping treatment.
Can vutrisiran set a new first-line standard in ATTR-CM after HELIOS-B trial results?
Alnylam’s HELIOS-B data shows vutrisiran cuts GI events by up to 49% in ATTR-CM, reinforcing its case as a first-line therapy. Read the full analysis.
How do Vutrisiran’s HELIOS-B results compare with historical standards in ATTR-CM treatment?
Alnylam’s vutrisiran reduces cardiovascular mortality and urgent heart failure visits in ATTR-CM, reinforcing AMVUTTRA’s first-line potential. Read key data now.
Vutrisiran : Alnylam Pharmaceuticals reveals positive results from HELIOS-B Phase 3 study
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, has unveiled promising results from the…